The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2017 Mar 2

PMID 28247334

Citations 76

Authors

Zhijuan Mao

Chanchan Liu

Suqiong Ji

Qingmei Yang

Hongxiang Ye

Haiyan Han

Zheng Xue

Affiliations

Soon will be listed here.

Abstract

The etiology and pathogenesis of Parkinson's disease (PD) are complicated and have not been fully elucidated, but an important association has been identified between inflammation and PD. In this study, we investigated the role of the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing (NLRP) 3 inflammasome, consisting of NLRP3, caspase-1 and cytokines of the IL-1 family, in lipopolysaccharide (LPS)-induced and 6-hydroxydopamine (6-OHDA)-induced PD rats. Microinjection of different doses of caspase-1 inhibitor (Ac-YVAD-CMK, 300 or 1200 ng/rat) was performed for seven consecutive days. Then, rotational behavior, the number of dopamine (DA) neurons in the substantia nigra pars compacta (SNc), and the mRNA and protein expression levels of NLRP3 inflammasome components were measured 14 days after the microinjection setup was established. Results showed that high mRNA and protein expression levels of NLRP3 inflammasome components were observed in the injected side of the LPS- and 6-OHDA-induced PD rats; Ac-YVAD-CMK inhibited the mRNA and protein expression of NLRP3 inflammasome components in both LPS- and 6-OHDA-induced PD rats. Moreover, the number of rotations was significantly decreased, and the number of DA neurons in the SNc improved. Our data indicate that the NLRP3 inflammasome participates in the pathogenesis of PD and that inhibiting the downstream pathway of the NLRP3/caspase-1/IL-1β axis can alleviate the occurrence of PD symptoms, providing a new basis for the prevention and treatment of PD.

Citing Articles

NLRP3 inflammasome in neuroinflammation and central nervous system diseases.

Xu W, Huang Y, Zhou R Cell Mol Immunol. 2025; .

PMID: 40075143 DOI: 10.1038/s41423-025-01275-w.

NLRP3 inflammasome in health and disease (Review).

Wang H, Ma L, Su W, Liu Y, Xie N, Liu J Int J Mol Med. 2025; 55(3).

PMID: 39930811 PMC: 11781521. DOI: 10.3892/ijmm.2025.5489.

Carvacrol attenuated haloperidol-induced Parkinson's disease via TNF/NFκβ-NLRP3-mediated pyroptosis.

Albaqami F, Ahmad K, Shah F Lab Anim Res. 2025; 41(1):7.

PMID: 39910608 PMC: 11796269. DOI: 10.1186/s42826-025-00237-7.

Short-Chain Fatty Acid Aggregates Alpha-Synuclein Accumulation and Neuroinflammation via GPR43-NLRP3 Signaling Pathway in a Model Parkinson's Disease.

Qu Y, An K, Wang D, Yu H, Li J, Min Z Mol Neurobiol. 2025; .

PMID: 39904963 DOI: 10.1007/s12035-025-04726-7.

Neuroinflammation in Age-Related Neurodegenerative Diseases: Role of Mitochondrial Oxidative Stress.

Abadin X, de Dios C, Zubillaga M, Ivars E, Puigros M, Mari M Antioxidants (Basel). 2025; 13(12.

PMID: 39765769 PMC: 11672511. DOI: 10.3390/antiox13121440.

References

Eda H, Shimada H, Beidler D, Monahan J . Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts. Rheumatol Int. 2010; 31(11):1525-30. DOI: 10.1007/s00296-010-1688-7. View

House S, Mao X, Wu G, Espinelli D, Li W, Chang S . Chronic morphine potentiates the inflammatory response by disrupting interleukin-1beta modulation of the hypothalamic-pituitary-adrenal axis. J Neuroimmunol. 2001; 118(2):277-85. DOI: 10.1016/s0165-5728(01)00337-x. View

Griffin W, Liu L, Li Y, Mrak R, Barger S . Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation. 2006; 3:5. PMC: 1435743. DOI: 10.1186/1742-2094-3-5. View

Schierle G, Hansson O, Leist M, Nicotera P, Widner H, Brundin P . Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med. 1999; 5(1):97-100. DOI: 10.1038/4785. View

Heneka M, Carson M, El Khoury J, Landreth G, Brosseron F, Feinstein D . Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388-405. PMC: 5909703. DOI: 10.1016/S1474-4422(15)70016-5. View

Liang C, Xu Y, Zheng D, Sun X, Xu Q, Duan D . RNAi-mediated silencing of HLA A2 suppressed acute rejection against human fibroblast xenografts in the striatum of 6-OHDA lesioned rats. J Neuroimmunol. 2016; 297:28-37. DOI: 10.1016/j.jneuroim.2016.05.002. View

Seki E, Tsutsui H, Nakano H, Tsuji N, Hoshino K, Adachi O . Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol. 2001; 166(4):2651-7. DOI: 10.4049/jimmunol.166.4.2651. View

Kim W, Mohney R, Wilson B, Jeohn G, Liu B, Hong J . Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000; 20(16):6309-16. PMC: 6772569. View

Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S . Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000; 25(3):302-5. DOI: 10.1038/77060. View

10.

Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci M . Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci. 2002; 15(1):120-32. DOI: 10.1046/j.0953-816x.2001.01843.x. View

11.

Chen Y, Dorn 2nd G . PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science. 2013; 340(6131):471-5. PMC: 3774525. DOI: 10.1126/science.1231031. View

12.

Worlitzer M, Bunk E, Hemmer K, Schwamborn J . Anti-inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice. Stem Cell Res Ther. 2012; 3(4):33. PMC: 3580471. DOI: 10.1186/scrt124. View

13.

Hoban D, Connaughton E, Connaughton C, Hogan G, Thornton C, Mulcahy P . Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav Immun. 2012; 27(1):91-100. DOI: 10.1016/j.bbi.2012.10.001. View

14.

Coll R, Robertson A, Chae J, Higgins S, Munoz-Planillo R, Inserra M . A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21(3):248-55. PMC: 4392179. DOI: 10.1038/nm.3806. View

15.

Pott Godoy M, Tarelli R, Ferrari C, Sarchi M, Pitossi F . Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain. 2008; 131(Pt 7):1880-94. PMC: 2442423. DOI: 10.1093/brain/awn101. View

16.

Li X, Zhang Y, Xia M, Gulbins E, Boini K, Li P . Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration: implication of a novel role of inflammasome in atherogenesis. PLoS One. 2014; 9(1):e87552. PMC: 3903678. DOI: 10.1371/journal.pone.0087552. View

17.

Hirsch E, Vyas S, Hunot S . Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S210-2. DOI: 10.1016/S1353-8020(11)70065-7. View

18.

Sarre S, Yuan H, Jonkers N, Van Hemelrijck A, Ebinger G, Michotte Y . In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem. 2004; 90(1):29-39. DOI: 10.1111/j.1471-4159.2004.02471.x. View

19.

Chakraborty S, Kaushik D, Gupta M, Basu A . Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res. 2010; 88(8):1615-31. DOI: 10.1002/jnr.22343. View

20.

Bauernfeind F, Ablasser A, Bartok E, Kim S, Schmid-Burgk J, Cavlar T . Inflammasomes: current understanding and open questions. Cell Mol Life Sci. 2010; 68(5):765-83. PMC: 11114650. DOI: 10.1007/s00018-010-0567-4. View